Skip to main content
Erschienen in: Medical Oncology 3/2012

01.09.2012 | Original Paper

CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis

verfasst von: Peng Xu, Xiao-Lan Xu, Qiang Huang, Zhi-Hong Zhang, Yan-Bei Zhang

Erschienen in: Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) and survivin are aberrantly expressed in a wide range of human cancers, including lung tumors. In order to assess the expressions of these two proteins in Chinese non-small-cell lung cancer (NSCLC) patients and determine their correlation with prognosis, NSCLC tissues and adjacent non-cancerous normal lung tissues were collected from 97 patients undergoing surgical treatment and evaluated by immunohistochemistry staining. CIP2A or survivin immunoreactivity was detected in significantly more NSCLC tissues than in adjacent non-cancerous lung tissues (P < 0.05). Moreover, CIP2A expression in NSCLC correlated with TNM stage, while survivin expression correlated with TNM stage and lymph node metastasis. Kaplan–Meier survival analysis showed that the overall survival times in patients expressing either CIP2A or survivin protein in NSCLC were shorter. COX regression analysis indicated that expression of CIP2A protein was an independent prognostic factor for NSCLC patients (HR = 3.631, P = 0.015). Therefore, CIP2A expression in Chinese NSCLC patients may be a useful biomarker of biological malignancy.
Literatur
1.
Zurück zum Zitat Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Eng J Med. 2004;350:379–92.CrossRef Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Eng J Med. 2004;350:379–92.CrossRef
3.
Zurück zum Zitat Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang E. H:CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18:857–65.PubMedCrossRef Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang E. H:CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18:857–65.PubMedCrossRef
4.
Zurück zum Zitat Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 2010;70:10402–10.PubMedCrossRef Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 2010;70:10402–10.PubMedCrossRef
5.
Zurück zum Zitat Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21:5006–15.PubMedCrossRef Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21:5006–15.PubMedCrossRef
6.
Zurück zum Zitat Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722–8.PubMedCrossRef Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722–8.PubMedCrossRef
7.
Zurück zum Zitat Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793–805.PubMedCrossRef Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793–805.PubMedCrossRef
8.
Zurück zum Zitat Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092–100.PubMedCrossRef Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092–100.PubMedCrossRef
9.
Zurück zum Zitat Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62.PubMedCrossRef Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62.PubMedCrossRef
10.
Zurück zum Zitat Basile JR, Czerninski R. The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther. 2010;10:700–2.PubMedCrossRef Basile JR, Czerninski R. The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther. 2010;10:700–2.PubMedCrossRef
11.
Zurück zum Zitat Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.PubMedCrossRef Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.PubMedCrossRef
12.
Zurück zum Zitat Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol. 2005;247:35–88.PubMedCrossRef Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol. 2005;247:35–88.PubMedCrossRef
13.
Zurück zum Zitat Vaarala MH, Vaisanen MR, Ristimaki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010;29:136.PubMedCrossRef Vaarala MH, Vaisanen MR, Ristimaki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010;29:136.PubMedCrossRef
14.
Zurück zum Zitat Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 2001;7:542–7.PubMedCrossRef Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 2001;7:542–7.PubMedCrossRef
Metadaten
Titel
CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis
verfasst von
Peng Xu
Xiao-Lan Xu
Qiang Huang
Zhi-Hong Zhang
Yan-Bei Zhang
Publikationsdatum
01.09.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0053-3

Weitere Artikel der Ausgabe 3/2012

Medical Oncology 3/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.